Indication · Radiology & Imaging
Breast cancer
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
610
Cleared or approved since 2000
PMA and De Novo
79
Higher-risk or first-of-kind devices
Breakthrough devices
6
Authorized through June 30, 2026
Recruiting device trials
172
1,216 device trials in all
Breakthrough-designated devices
- Claire OCT SystemPerimeter Medical Imaging Ai, Inc. · 2026
5 more devices with a free account
Devices
610 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Ventana Medical Systems, Inc. · PMA · System, Test, Her-2/Neu, Ihc · newest 2026 · 12 decisions
59 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast CancerNot yet recruiting
Jin Sun BitarAcademic, hospital or other
NCT07950007 · 60 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 1, 2029
Device: ctDNA Testing Blood Test · For: HER2 + Breast Cancer
Sites: Beverly Hills, California
1,215 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Instrument, Biopsy (KNW)183
- Marker, Radiographic, Implantable (NEU)92
- Full Field Digital, System, X-Ray, Mammographic (MUE)69
- System, X-Ray, Mammographic (IZH)43
- Cabinet, X-Ray System (MWP)24
- System, Therapeutic, X-Ray (JAD)23
- Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer (QDQ)23
- Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer (POK)16
- System, Test, Immunological, Antigen, Tumor (MOI)15
- Immunohistochemistry Antibody Assay, Estrogen Receptor (MYA)11
- Immunohistochemistry Assay, Antibody, Progesterone Receptor (MXZ)10
- Digital Breast Tomosynthesis (OTE)10
- System, Test, Her-2/Neu, Ihc (MVC)8
- Microscope, Automated, Image Analysis, Immunohistochemistry,Operator Intervention,Nuclear Intensity & Percent Positivity (NQN)7
- Automated Breast Ultrasound (PAA)7
- System, Test, Her-2/Neu, Nucleic Acid Or Serum (MVD)6
- Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ)6
- Scalp Cooling System (PMC)6
- Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI)5
- Automated Digital Image Manual Interpretation Microscope (OEO)5
- Temporary Tissue Marker (PBY)5
- System, Imaging, Holography, Acoustic (NCS)3
- System, Test, Her-2/Neu, Monitoring (NCW)3
- System, Documentation, Breast Lesion (NKA)3
- Internal Tissue Marker (PDW)3
- Cancer-Related Germline Gene Mutation Detection System (PJG)3
- Sheet, Recording, Breast Examination (NHM)2
- Control Material, Her-2/Neu, Immunohistochemistry (NJW)2
- Diagnostic Low Electric Field (OEE)2
- Lymph Node Location System During Sentinel Biopsy Procedure (PUV)2
Research
- Device studies on breast cancer across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.